RAF1 and neoplasm: Regorafenib inhibits multiple tyrosine kinases involved in tumor angiogenesis (VEGFR1-3, TIE2), oncogenic transformation (KIT, RET, RAF1, BRAF), and shaping tumor microenvironment (PDGFR, FGFR) (42).